pharmaphorum

MARCH 15, 2022

The TruSight Oncology in vitro diagnostic (IVD) test is being launched first in Europe and according to Illumina’s cancer head Kevin Keegan can match patients with suitable therapies “according to clinical guidelines or clinical trials, based on their tumour profile.”

Gene 52

Gene Genome Genomics Gene Sequencing 52

Roots Analysis

SEPTEMBER 4, 2024

The main purpose of in vitro diagnostic solutions is to perform non-invasive / minimally invasive test procedures in order to detect a variety of health conditions using samples, such as blood, tissue or urine. Such tests help to diagnose health conditions, monitor treatments, perform disease screening and aid in early diagnosis of diseases.

Marketing 40

Marketing In-Vitro Compliance Development 40

XTalks

JANUARY 21, 2025

From non-invasive cancer diagnostics to life-saving cardiovascular implants, the latest medical devices cleared or approved by the FDA in 2024 reflect the remarkable strides in science and engineering. In this blog, we discuss some of these new medical devices of 2024 that have improved patient outcomes and enhanced quality of life worldwide.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

XTalks

SEPTEMBER 30, 2020

In collaboration with clinicians around the world, Casanova’s team studied the genomes of COVID-19 patients, focusing on a set of 13 genes involved in interferon immunity against influenza. The findings reveal a critical role for IFNs in fighting COVID-19 infection, positioning them to be a potential therapeutic target in the disease.

Antibody 135

Antibody Genetics Research In-Vitro 135

Pharmaceutical Technology

AUGUST 26, 2008

“However, around the time of the Human Genome Project, there was a ‘land grab’ for the new technologies as big pharmaceuticals tried to catch up paying high prices to access technology platforms in areas such as genomics and high throughput screening.” “Biotechnology has exploded across the industry. .

Antibody 100

Antibody Licensing Licensing Production 100

BioSpace

JULY 3, 2022

Rather than selling, Novartis could spin Sandoz off into its own separate entity with its own listing on a stock exchange.

Marketing 40

Marketing In-Vitro Genome Genomics 40

Roots Analysis

MARCH 16, 2023

In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. mRNA drugs are considered to offer an effective alternative to gene therapies, specifically for protein replacement, as they avoid the risk of genome integration and offer strong transient expression.

Vaccination 52

Vaccination Vaccine DNA Protein 52

The Pharma Data

DECEMBER 22, 2020

Available since 2017 as an in vitro diagnostic assay (IVD) in Europe and the United States, Japanese clinical geneticists can now have access to this assay to help identify a definitive genetic diagnosis for their patients. SANTA CLARA, Calif.–( –( BUSINESS WIRE )– Agilent Technologies Inc.

Genome 40

Genome Genomics Genetics In-Vitro 40

pharmaphorum

OCTOBER 29, 2020

The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression. The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression.

Development 45

Development DNA In-Vitro Genome 45

The Pharma Data

DECEMBER 14, 2020

engine along with algorithms tuned to predict BBB permeability played an important role in helping determine which CNS cancers and which genomically-defined subtypes of CNS cancer should be prioritized for development. . We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I.

Drugs 52

Drugs Genome Genomics DNA 52

The Pharma Data

SEPTEMBER 28, 2021

About the cobas omni Utility Channel on the cobas 6800/8800 Systems The cobas omni Utility Channel on the cobas 6800/8800 Systems enables a broader testing menu by consolidating open channel assays with Roche in vitro diagnostic (IVD) assays on one platform.

Marketing 52

Marketing In-Vitro DNA Bacteria 52

XTalks

NOVEMBER 7, 2022

These tumor-derived entities are used to derive genomic and proteomic data. Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. The same webinar held a Q&A session with Dr. Bahassi and two other experts from Medpace, Dr. Lyon L.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

XTalks

DECEMBER 11, 2023

Medical device companies continue to maintain a crucial role in enhancing patient care and diagnostic precision in 2023. Let’s examine the list of the top ten fastest growing medical device companies in 2023, ranked by their compound annual growth rate (CAGR). In 2021, Axonics achieved an impressive revenue of $180.3

Production 110

Production Sales In-Vitro Development 110

The Pharma Data

NOVEMBER 17, 2021

Streamlined in vitro data, published in bioRxiv, demonstrate that sotrovimab retains exertion against all current variants of concern and interest of the SARS-CoV-2 contagion as defined by the World Health Organization, plus others, including, but not limited to, Delta (B.1.617.2), 1.617.2), Delta Plus (AY.1 2) and Mu (B.1.621).

Antibody 52

Antibody In-Vitro Vaccination Vaccine 52

The Pharma Data

NOVEMBER 14, 2021

The ranking acknowledges Roche’s commitment to sustainability as an integral part of its business strategy Roche performed particularly well in Operational Eco-Efficiency, Environmental and Social Reporting. This is based on an in-depth analysis of economic, social and environmental performance.

In-Vitro 52

In-Vitro Medicine Genome Genomics 52

Roots Analysis

AUGUST 12, 2024

Molecular diagnostic tests are advanced techniques and tools used to analyze biological markers in the genome and proteome. Molecular diagnostic tests refer to tests intended to detect specific sequences in human genomic samples, such as DNA or RNA, in order to diagnose a particular disease.

Genetics 40

Genetics Gene Expression RNA DNA 40

The Pharma Data

NOVEMBER 5, 2021

Roche intends to cancel the shares repurchased from Novartis after completion of the repurchase. Roche confirms the outlook for the year 2021 and is aiming at increasing the dividend in Swiss francs also for 2021. Roche and Novartis have announced today that they agreed on a repurchase by Roche of the 53.3 million Roche shares held by Novartis.

In-Vitro 52

In-Vitro Sales Genome Genomics 52

The Pharma Data

JANUARY 11, 2021

Dalcetrapib is a potential anti-viral treatment that binds to the catalytic site of 3CLMpro of SARS-CoV-2 in vitro. Centers for Disease Control and Prevention (CDC) to provide genomic sequencing of SARS-CoV-2 samples. News information is not all-inclusive and updates are published once a week on Tuesdays. . . Diagnostics.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Cloudbyz

JULY 31, 2024

The landscape of modern medicine is rapidly evolving, driven by groundbreaking advancements in diagnostics. This revolution is enabling the growth of innovative biomarker-based precision medicine and cell and gene therapy, transforming both clinical research and post-market care.

Gene Therapy 52

Gene Therapy Gene Medicine In-Vitro 52

FDA Law Blog

MAY 25, 2022

It is not uncommon for some in vitro diagnostic tests to suffer from poor positive predictive value, in part due to the rarity of the disease. The VALID Act would give FDA authority to regulate laboratory developed tests and fundamentally change the regulatory paradigm for all in vitro diagnostic tests. (As

Regulation 40

Regulation Genetics In-Vitro Development 40

The Pharma Data

OCTOBER 9, 2021

Roche (SIX RO, ROG; OTCQX RHHBY) now posted that gantenerumab, ananti-amyloid beta antibody developed for subcutaneous administration, has been granted Improvement Rectifier Designation by theU.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice).

Antibody 52

Antibody In-Vitro Trials Development 52

The Pharma Data

OCTOBER 14, 2021

Roche today announced European Medicines Agency (EMA) approval of a new, shorter 90-minute Gazyvaro® (obinutuzumab) infusion time, administered in combination with chemotherapy in patients with previously treated or untreated advanced follicular lymphoma (FL). Roche’s Chief Medical Officer and Head of Global Product Development.

Medicine 52

Medicine In-Vitro Antibody Genome 52

The Pharma Data

NOVEMBER 23, 2021

Roche moment blazoned that new data from its expansive haematology portfolio will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from 11-14 December 2021. The safety profile was similar for Polivy plus R-CHP versus R-CHOP.1 Roche’s Chief Medical Officer and Head of Global Product Development. “

Antibody 52

Antibody In-Vitro Development Genome 52

The Pharma Data

OCTOBER 14, 2021

This designation is based on data showing that gantenerumab significantly reduced brain amyloid plaque, a pathological hallmark of AD, in the ongoing SCarlet RoAD and Marguerite RoAD open-label extension trials, as well as other studies. Roche’s Chief Medical Officer and Head of Global Product Development.

Antibody 52

Antibody Medicine In-Vitro Trials 52

XTalks

NOVEMBER 19, 2021

Cardiac biomarkers can not only serve important roles in the diagnosis, management and prognosis of cardiac diseases, but they can also be significant tools in evaluating treatments in cardiovascular (CV) clinical trials. They can be used in patient selection, stratification, risk mitigation and assessment of safety and efficacy endpoints.

Clinical Trials 98

Clinical Trials Clinical Trials Trials In-Vitro 98

The Pharma Data

FEBRUARY 25, 2022

“SARS-CoV-2 produces long proteins, called polyproteins, from its RNA genome that must be cleaved into individual proteins by these proteases in an ordered fashion leading to the formation of functional virus enzymes and proteins to start virus replication once it enters a cell,” Murakami explained.

FDA Approval 52

FDA Approval Drugs Protein In-Vitro 52

The Pharma Data

MAY 4, 2021

Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study. Tecentriq approval offers an alternative to chemotherapy for all eligible patients. We are delighted to bring Tecentriq to people in the EU with this specific type of lung cancer,” said Levi Garraway, M.D.,

Protein 52

Protein HR In-Vitro Medicine 52

The Pharma Data

JANUARY 24, 2021

Brilacidin has shown in vitro to be have antiviral properties against different SARS-CoV-2 strains and other human coronaviruses. With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see. COVID-19-Related. Non-COVID-19-Related.

Trials 52

Trials Allergies In-Vitro Antibody 52

XTalks

AUGUST 12, 2020

Despite the effectiveness of anti-retroviral therapy (ART) in significantly improving health, quality of life and reducing mortality among HIV-positive individuals, new research shows that persistent infections may be due to the ability of the virus to take refuge in distinct subsets of immune T cells.

RNA 52

RNA Protein DNA In-Vivo 52

The Pharma Data

SEPTEMBER 6, 2020

We remain committed to finding personalised treatment options for people with cancer based on specific genomic or molecular alterations, and we look forward to partnering with Blueprint Medicines to further explore the potential of Gavreto across multiple RET-altered tumour types.”. months, not reached). 2 The most common adverse reactions (?

FDA Approval 52

FDA Approval Medicine In-Vitro Genetics 52

The Pharma Data

NOVEMBER 12, 2021

EU marketing authorisation follows approvals in Japan, the United Kingdom and Australia Approval based on data demonstrating Ronapreve reduced risk of hospitalisation in certain patients with mild to moderate disease and reduced risk of symptomatic COVID-19 infections in people exposed to the virus.

In-Vitro 40

In-Vitro Medicine Development Marketing 40

The Pharma Data

NOVEMBER 11, 2021

A final decision regarding the blessing of Ronapreve is anticipated from the European Commission in the near future. Roche’s Chief Medical Officer and Head of Global Product Development.”People It has also been conditionally recommended by WHO.

In-Vitro 40

In-Vitro Antibody Medicine Development 40

The Pharma Data

JULY 21, 2021

Group sales up 8% 1 at constant exchange rates (CER); 5% in Swiss francs. Pharmaceuticals Division sales decline 3%; sales grow 4% in the second quarter, following a first-quarter decrease of 9%; newly launched medicines (+30%) compensate for the continued impact from biosimilars. Outlook for 2021 confirmed. Group results.

Sales 52

Sales Medicine Antibody In-Vitro 52

The Pharma Data

MARCH 16, 2021

1 lineage gained prominence in late 2020, with each carrying a number of genomic mutations. The cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in virus variants associated with increased human-to-human transmission. 1.1.7), South Africa (B.1.351), 1.351), and Brazil (P.1). Variants of B.1.1.7, 1.351 and P.1

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccination 52

The Pharma Data

MARCH 26, 2021

New in vitro data from pseudotyped virus assays published online in bioRxiv in March 2021 support this hypothesis as they demonstrate that VIR-7831 maintains activity against current circulating variants of concern including the UK, South African and Brazilian variants. About the VIR-7831 Clinical Development Programme.

Antibody 52

Antibody Trials Vaccination Vaccine 52

The Pharma Data

DECEMBER 2, 2020

Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. About Progenity. Progenity, Inc. Progenity, Inc.

In-Vitro 40

In-Vitro Sales Containment Development 40

The Pharma Data

SEPTEMBER 16, 2020

New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers. New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Join this event on Roche’s LinkedIn page here. Roche highlights featured at ESMO Virtual Congress 2020.

HR 52

HR Medicine Hormones Trials 52